AAAAAA

   
Results: 1-20 |
Results: 20
Antibodies to prothrombin, factor V, and beta(2)-glycoprotein I and vascular access thrombosis
Authors: Sands, JJ Nudo, SA Moore, KD Ortel, TL
Citation: Jj. Sands et al., Antibodies to prothrombin, factor V, and beta(2)-glycoprotein I and vascular access thrombosis, ASAIO J, 47(5), 2001, pp. 507-510
beta(2)-glycoprotein I-dependent anticardiolipin antibodies preferentiallybind the amino terminal domain of beta(2)-glycoprotein I
Authors: McNeeley, PA Dlott, JS Furie, RA Jack, RM Ortel, TL Triplett, DA Victoria, EJ Linnik, MD
Citation: Pa. Mcneeley et al., beta(2)-glycoprotein I-dependent anticardiolipin antibodies preferentiallybind the amino terminal domain of beta(2)-glycoprotein I, THROMB HAEM, 86(2), 2001, pp. 590-595
Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants - Identification of two antigenic epitopes involved in phospholipid binding
Authors: Izumi, T Kim, SW Greist, A Macedo-Ribeiro, S Fuentes-Prior, P Bode, W Kane, WH Ortel, TL
Citation: T. Izumi et al., Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants - Identification of two antigenic epitopes involved in phospholipid binding, THROMB HAEM, 85(6), 2001, pp. 1048-1054
Factor VIII Arg2304 -> His binds to phosphatidylserine and is a functionalcofactor in the factor X-ase complex
Authors: Lewis, DA Moore, KD Ortel, TL
Citation: Da. Lewis et al., Factor VIII Arg2304 -> His binds to phosphatidylserine and is a functionalcofactor in the factor X-ase complex, THROMB HAEM, 85(2), 2001, pp. 260-264
Risk factors associated with thrombosis in patients with antiphospholipid antibodies
Authors: Hansen, KE Kong, DF Moore, KD Ortel, TL
Citation: Ke. Hansen et al., Risk factors associated with thrombosis in patients with antiphospholipid antibodies, J RHEUMATOL, 28(9), 2001, pp. 2018-2024
Tissue factor in experimental acute lung injury
Authors: Welty-Wolf, KE Carraway, MS Idell, S Ortel, TL Ezban, M Piantadosi, CA
Citation: Ke. Welty-wolf et al., Tissue factor in experimental acute lung injury, SEM HEMATOL, 38(4), 2001, pp. 35-38
Immunologic impact and clinical outcomes after surgical exposure to bovinethrombin
Authors: Ortel, TL Mercer, MC Thames, EH Moore, KD Lawson, JH
Citation: Tl. Ortel et al., Immunologic impact and clinical outcomes after surgical exposure to bovinethrombin, ANN SURG, 233(1), 2001, pp. 88-96
Exposure of mice to topical bovine thrombin induces systemic autoimmunity
Authors: Schoenecker, JG Johnson, RK Lesher, AP Day, JD Love, SD Hoffman, MR Ortel, TL Parker, W Lawson, JH
Citation: Jg. Schoenecker et al., Exposure of mice to topical bovine thrombin induces systemic autoimmunity, AM J PATH, 159(5), 2001, pp. 1957-1969
Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglinanomaly
Authors: Kelley, MJ Jawien, W Ortel, TL Korczak, JF
Citation: Mj. Kelley et al., Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglinanomaly, NAT GENET, 26(1), 2000, pp. 106-108
Assessment of primary hemostasis by PFA-100 (R) analysis in a tertiary care center
Authors: Ortel, TL James, AH Thames, EH Moore, KD Greenberg, CS
Citation: Tl. Ortel et al., Assessment of primary hemostasis by PFA-100 (R) analysis in a tertiary care center, THROMB HAEM, 84(1), 2000, pp. 93-97
Antibodies to topical bovine thrombin correlate with access thrombosis
Authors: Sands, JJ Nudo, SA Ashford, RG Moore, KD Ortel, TL
Citation: Jj. Sands et al., Antibodies to topical bovine thrombin correlate with access thrombosis, AM J KIDNEY, 35(5), 2000, pp. 796-801
Two instruments to determine activated partial thromboplastin time: Implications for heparin monitoring
Authors: Taylor, CT Petros, WP Ortel, TL
Citation: Ct. Taylor et al., Two instruments to determine activated partial thromboplastin time: Implications for heparin monitoring, PHARMACOTHE, 19(4), 1999, pp. 383-387
Crystal structures of the membrane-binding C2 domain of human coagulation factor V
Authors: Macedo-Ribeiro, S Bode, W Huber, R Quinn-Allen, MA Kim, SW Ortel, TL Bourenkov, GP Bartunik, HD Stubbs, MT Kane, WH Fuentes-Prior, P
Citation: S. Macedo-ribeiro et al., Crystal structures of the membrane-binding C2 domain of human coagulation factor V, NATURE, 402(6760), 1999, pp. 434-439
Clinical and laboratory manifestations of anti-factor V antibodies
Authors: Ortel, TL
Citation: Tl. Ortel, Clinical and laboratory manifestations of anti-factor V antibodies, J LA CL MED, 133(4), 1999, pp. 326-334
Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex
Authors: Kim, SW Ortel, TL Quinn-Allen, MA Yoo, L Worfolk, L Zhai, X Lentz, BR Kane, WH
Citation: Sw. Kim et al., Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex, BIOCHEM, 38(35), 1999, pp. 11448-11454
Familial antiphospholipid antibody syndrome - Criteria for disease and evidence for autosomal dominant inheritance
Authors: Goel, N Ortel, TL Bali, D Anderson, JP Gourley, IS Smith, H Morris, CA DeSimone, M Branch, DW Ford, P Berdeaux, D Roubey, RAS Kostyu, DD Kingsmore, SF Thiel, T Amos, C Seldin, MF
Citation: N. Goel et al., Familial antiphospholipid antibody syndrome - Criteria for disease and evidence for autosomal dominant inheritance, ARTH RHEUM, 42(2), 1999, pp. 318-327
Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa
Authors: Hansen, KE Moore, KD Ortel, TL Allen, NB
Citation: Ke. Hansen et al., Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa, ARTH RHEUM, 42(10), 1999, pp. 2250-2252
Genetics of coagulation disorders
Authors: Ortel, TL
Citation: Tl. Ortel, Genetics of coagulation disorders, GENETICS OF CEREBROVASCULAR DISEASE, 1999, pp. 129-156
Heparin-induced thrombocytopenia
Authors: Ortel, TL
Citation: Tl. Ortel, Heparin-induced thrombocytopenia, SEM HEMATOL, 35(4), 1998, pp. 1-2
New treatment options for heparin-induced thrombocytopenia
Authors: Ortel, TL Chong, BH
Citation: Tl. Ortel et Bh. Chong, New treatment options for heparin-induced thrombocytopenia, SEM HEMATOL, 35(4), 1998, pp. 26-34
Risultati: 1-20 |